Abstract 474P
Background
We investigated KCNJ11 expression in different glioma tissue subtypes and its use as a predictor of glioma prognosis and sensitivity to temozolomide chemotherapy and determined the value of performance evaluation indicators.
Methods
Data on sex, age, histopathological type, WHO grade, IDH mutation, 1p/19q deletion, survival time, and KCNJ11 mRNA were collected from 516 patients with glioma. Expression levels and other data and uni- and multivariate Cox regression analyses were used to determine prognostic factors for patients with glioma. Data obtained from 603 cases with different glioma subtypes in TCGA database, 284 cases in REMBRANDT, and 264 cases in the United States database of the National Center for Biotechnology Information were verified to correlate KCNJ11 mRNA expression levels with the relationship between different clinical features and overall survival.
Results
KCNJ11 mRNA expression in 516 patients with different glioma subtypes correlated with histopathological type, WHO grade, IDH mutation status, 1p/19q co-deletion status, MGMT methylation, and WHO molecular classification (both P<0.05). Median survival times in the high KCNJ11 mRNA expression group were longer than those in the low expression group (P<0.05). Multivariate Cox regression analysis showed that age, tumor recurrence, WHO classification, IDH mutation, 1p/19q co-deletion, postoperative chemotherapy, and KCNJ11 mRNA expression were independent influencing factors of overall patient survival time. In the TCGA dataset, median overall survival times in the high expression group were longer than those in the low expression group (P<0.05). In the REMBRANDT dataset, median overall survival times in the high expression group was longer than those in the low expression group (P<0.05). In the GSE1101 dataset, median overall survival times in the high expression group was longer than those in the low expression group (P<0.05).
Conclusions
KCNJ11 mRNA expression was related to the degree of tumor malignancy and was an independent factor affecting overall survival time, and overall survival times of patients with high KCNJ11 mRNA expression are longer than those of patients with low KCNJ11 mRNA expression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
K. Zhou.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
547P - Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer
Presenter: Elio Adib
Session: Poster session 16
548P - Simplified immune score based on CD8+ T-cells at the invasive margin provides comparable prognostic value to immune scores in non-metastatic colorectal cancer
Presenter: Durgesh Wankhede
Session: Poster session 16
549P - Combined morphometric immune signatures define the prognosis of patients with resectable colorectal liver metastases
Presenter: Markus Moehler
Session: Poster session 16
550P - The impact of mismatch repair status on accuracy of clinical staging in upfront resected stage II/III rectal cancer in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
551P - Efficacy prediction of chemoradiotherapy plus anti-PD-1/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer
Presenter: Wentao Tang
Session: Poster session 16
552P - Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial
Presenter: James Platt
Session: Poster session 16
553P - Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Presenter: JUN NAGATA
Session: Poster session 16
555P - Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Presenter: TOMOYA HARIMA
Session: Poster session 16